Previous 10 | Next 10 |
Gainers: Inspire Medical Systems (INSP) +24%, GW Pharmaceuticals (GWPH) +15%, Aptevo Therapeutics (APVO) +14%, Galera Therapeutics (GRTX) +11%, DBV Technologies (DBVT) +10%.Losers: Esperion Therapeutics (ESPR) -15%, Aurinia Pharmaceuticals (AUPH)...
Beasley Broadcast Group (BBGI) +54% on Q3 results.Alaska Communications Systems Group (ALSK) +56% after announcing agreement to be acquired by Macquarie Capital and GCM Grosvenor for $3.0 per share.JAKKS Pacific (JAKK) +18% on Q3 results.trivago N.V. (TRVG) +15%....
Gainers: Endurance International (EIGI) +61%.Superior Industries International (SUP) +35%.DBV Technologies (DBVT) +32%.Renren (RENN) +22%.Digital Ally (DGLY) +21%.Dunxin Financial (DXF) +19%.Par Pacific Holdings (PARR) +18%.Tricida (TCDA) +18%.Lumber Liquidators (LL) +17%.Vislink Technol...
DBV Technologies (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company based in France that specializes in developing treatments for food allergies. On Monday, the company announced that the European Medicines Agency (EMA) had validated its Marketing Authorization Application...
Gainers: DBV Technologies (DBVT) +61%, AnPac Bio-Medical Science (ANPC) +16%, Community Health Systems (CYH) +15%, ProPhase Labs (PRPH) +12%, ZIOPHARM Oncology (ZIOP) +10%.Losers: Liquidia Technologies (LQDA) -28%, Jounce Therapeutics (JNCE) -...
DBV Technologies S.A. (DBVT) +80% as EMA approves Viaskin Peanut application.Endurance International Group Holdings (EIGI) +61% on announcing agreement to be acquired by Clearlake Capital Group L.P.AnPac Bio-Medical Science (ANPC) +30% as its Chinese company secu...
The EMA has validated DBV Technologies' (DBVT), +85% Marketing Authorization Application ((MAA)) for its investigational product Viaskin Peanut (DBV712).The validation confirms that the submission is sufficiently complete to begin the formal review process for the non-invasive, once...
Montrouge, France, November 2, 2020 DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT)...
Montrouge, France, October 30, 2020 DBV Technologies Reports September 30, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported its cash and cash equivalents...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN C...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...